BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2401092)

  • 1. Return of ovarian function following spontaneous abortion.
    Donnet ML; Howie PW; Marnie M; Cooper W; Lewis M
    Clin Endocrinol (Oxf); 1990 Jul; 33(1):13-20. PubMed ID: 2401092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of conception on the concentration of urinary oestrone-3-glucuronide, LH/hCG and pregnanediol-3 alpha-glucuronide.
    Branch CM; Collins PO; Kilpatrick MJ; Collins WP
    Acta Endocrinol (Copenh); 1980 Feb; 93(2):228-33. PubMed ID: 7376791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The concentrations of urinary oestrone-3-glucuronide, LH and pregnanediol-3alpha-glucuronide as indices of ovarian function.
    Collins WP; Collins PO; Kilpatrick MJ; Manning PA; Pike JM; Tyler JP
    Acta Endocrinol (Copenh); 1979 Feb; 90(2):336-48. PubMed ID: 419920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of ovarian follicle size and the urinary excretion of oestrone glucuronide, luteinizing hormone and pregnanediol glucuronide in spontaneous cycles.
    Adekunle AO; Collins WP; Whitehead MI
    Afr J Med Med Sci; 1988 Jun; 17(2):77-82. PubMed ID: 2843021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The return to ovulation following early abortion: a comparison between vacuum aspiration and prostaglandin.
    Cameron IT; Baird DT
    Acta Endocrinol (Copenh); 1988 Jun; 118(2):161-7. PubMed ID: 3291533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of reproductive hormonal dynamics in the perimenopause.
    Santoro N; Brown JR; Adel T; Skurnick JH
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1495-501. PubMed ID: 8636357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postpartum return of ovarian activity in nonbreastfeeding women monitored by urinary assays.
    Gray RH; Campbell OM; Zacur HA; Labbok MH; MacRae SL
    J Clin Endocrinol Metab; 1987 Apr; 64(4):645-50. PubMed ID: 3818896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of ovarian activity by daily measurement of urinary excretion rates of oestrone glucuronide and pregnanediol glucuronide using the Ovarian Monitor, Part III: variability of normal menstrual cycle profiles.
    Blackwell LF; Vigil P; Cooke DG; d'Arcangues C; Brown JB
    Hum Reprod; 2013 Dec; 28(12):3306-15. PubMed ID: 24170744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side of ovulation and cycle characteristics in normally fertile women.
    Ecochard R; Gougeon A
    Hum Reprod; 2000 Apr; 15(4):752-5. PubMed ID: 10739814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Return of ovarian function after abortion.
    Lähteenmäki P; Luukkainen T
    Clin Endocrinol (Oxf); 1978 Feb; 8(2):123-32. PubMed ID: 630723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of early pregnancy loss on hormone levels in the subsequent menstrual cycle.
    Jukic AM; Weinberg CR; Wilcox AJ; Baird DD
    Gynecol Endocrinol; 2010 Dec; 26(12):897-901. PubMed ID: 20504096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
    Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
    Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced follicle regulatory protein levels accompany reinitiation of ovulatory function after parturition.
    Albertson BD; Rodgers KE; Tomai TP; Nolan-Watson K; Zinaman MJ; DiZerega GS
    Am J Obstet Gynecol; 1992 Jul; 167(1):158-62. PubMed ID: 1442919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary hormone levels at the time of ovulation and implantation.
    Lasley BL; Stabenfeldt GH; Overstreet JW; Hanson FW; Czekala N; Munro C
    Fertil Steril; 1985 Jun; 43(6):861-7. PubMed ID: 3996630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of low daily doses of mifepristone on ovarian function and endometrial development.
    Danielsson KG; Swahn ML; Westlund P; Johannisson E; Seppälä M; Bygdeman M
    Hum Reprod; 1997 Jan; 12(1):124-31. PubMed ID: 9043916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the Home Ovarian Monitor in pregnancy avoidance.
    Brown JB; Holmes J; Barker G
    Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 2):2008-11. PubMed ID: 1755460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the dual analyte assay of the oestrone:pregnanediol ratio in monitoring ovarian function.
    Fabres C; Zegers-Hochschild F; Altieri E; Llados C
    Hum Reprod; 1993 Feb; 8(2):208-10. PubMed ID: 8473420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia.
    Bath LE; Anderson RA; Critchley HO; Kelnar CJ; Wallace WH
    Hum Reprod; 2001 Sep; 16(9):1838-44. PubMed ID: 11527885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.